Product Development Partnerships III Fund (PDP III)

The Product Development Partnerships III Fund (PDP III) focuses on the development and availability of affordable, effective medicines, vaccines, diagnostics and innovative products for neglected diseases and conditions. This contributes to the prevention, diagnostics and treatment of diseases and conditions related to poverty and sexual and reproductive health and rights (SRHR). The PDP III Fund is closed. You can no longer apply for this grant.

Budget

The available budget for the period 2015 to 2020 is € 86.3 million. The minimum grant application is € 1 million per year, and the maximum € 4 million per year. The activities for which a grant is sought must have a maximum duration of 5 years.

Criteria

Only Product Development Partnerships (PDPs) can apply for the fund. PDPs are public-private partnerships set up to accelerate the development and availability of products that are unlikely to attract private investment while in development.

PDPs have the following characteristics:

They are a partnership between public and private organisations that pool knowledge and know-how in order to work efficiently and effectively on a portfolio of new and/or improved demand-driven products to combat neglected diseases and conditions.

PDPs focus on the development and availability of affordable, effective medicines, vaccines, diagnostics and innovative products for neglected diseases and conditions, with a view to combating poverty and inequality.

They focus on developing products that would probably not be developed via standard commercial channels because of the failure of market forces. For example, because of the lack of purchasing power of a target group, or the lack of financial incentives for private sector investment.

PDPs involve diversified product portfolios. They work very efficiently, on the basis of professional management principles and governance structures with low overheads. They work on the basis of IPR agreements which ensure that products in development are made available as quickly as possible, and at the lowest possible price, to the people who need them most.

PDPs are funded by 2 or more donors representing different sectors, such as government, private sector, NGOs, trusts. These may be for-profit or non-profit (for example trusts) private sector organisations.

PDPs receive substantial in-cash or in-kind contributions from the private sector and research partners.

Financial and Progress administration

Partners are obliged to report to the Netherlands Enterprise Agency on their progress. The PDP contribution is reimbursed in predetermined instalments. All payments are advance payments.

Overview of PDP III projects

You can find all PDP III projects on Aiddata.rvo.nl. This portal offers an overview of all official development aid (ODA) projects and programmes executed by the Netherlands Enterprise Agency (RVO.nl). You can refine your search by using filter options such as country, sector and programme.

Background

There has been significant progress made over the last decade in research and development (R&D) and innovations in global health. But more than 10 million people worldwide are still dying each year from infectious diseases such as tuberculosis, HIV/AIDS, malaria and other poverty-related diseases and conditions. Many countries have large-scale shortages of effective, accessible and affordable medicines, vaccines, diagnostics and other healthcare products.

Also, women and children are still at greater risk of health problems due to unplanned pregnancies and unsafe abortions. Medicines and healthcare products often are not adapted to specific target groups such as young people and children, or to conditions in developing countries. This situation raises the mortality rate and prevents people from studying or contributing to their country’s productivity. This puts pressure on economic and development goals.

The target group’s lack of purchasing power and the lack of commercial incentives mean there is still insufficient investment in R&D and innovation in the areas of healthcare products and technologies. As a result, such products and technologies are all but non-existent - or unaffordable for the very poorest. Only a small proportion of global health research focuses on conditions that account for a large proportion of the global disease burden.

The PDP III fund is executed by the Netherlands Enterprise Agency (RVO.nl) for the Dutch Ministry of Foreign Affairs. The PDPs in this programme are part of the EDCPT2 Programme, supported by the European Union.

Official notice

The official notice for Product Development Partnerships III Fund (PDP III) was published in the Staatscourant.

Read the English translation of the official notice (pdf).

Annual meeting

On 23 May 2018 , the Ministry of Foreign Affairs hosted an annual meeting with representatives of the PDPs and Dutch policy makers at the BioSciencePark.

Read the report on the annual PDP meeting or watch the PDP meeting vlog.

Service menu right